Is NNC0174-0833 Approved? Early Amylin Status and Timeline (2026)
No. NNC0174-0833 is still a Phase 1 asset. It is part of Novo's deeper amylin bench, not a near-term approval candidate.
Current stage
Phase 1
Approval read
Not approved.
Likely window
2029 or later if it advances successfully.
Next step
Show enough early human signal to justify its place inside Novo's broader satiety pipeline.
Direct answer
No. NNC0174-0833 is still a Phase 1 asset. It is part of Novo's deeper amylin bench, not a near-term approval candidate.
Status facts for search and AI answers
What this NNC0174-0833 status page answers
Compound
NNC0174-0833
NNC0174-0833 is tracked as a Amylin program from Novo Nordisk.
Approval read
Not approved.
No. NNC0174-0833 is still a Phase 1 asset. It is part of Novo's deeper amylin bench, not a near-term approval candidate.
Likely window
2029 or later if it advances successfully.
The likely window is a FormBlends tracking read, not a guarantee of patient access.
Next step
Show enough early human signal to justify its place inside Novo's broader satiety pipeline.
This is the milestone most likely to change the page's answer.
Decision path
What does NNC0174-0833's status mean for access?
NNC0174-0833's approval status should be read as a regulatory signal, not a shortcut to buying or prescribing. The useful decision is whether this is approved, decision-stage, investigational, or simply worth monitoring.
- Compound
- NNC0174-0833
- Stage
- Phase 1
- Approval read
- Not approved.
- Window
- 2029 or later if it advances successfully.
Step 1
Classify availability
Phase 1 amylin-pathway program with strategic value but a long development road.
Read compound pageStep 2
Watch required milestone
Show enough early human signal to justify its place inside Novo's broader satiety pipeline.
Open pipeline trackerStep 3
Use current-care rules
If you need care now, separate trial-stage news from provider-reviewed GLP-1 options that can actually be prescribed.
Compare care routesWhat the status means now
Phase 1 amylin-pathway program with strategic value but a long development road.
It matters because it shows how much Novo is building behind the visible amylin names, not just around them.
What needs to happen next
Show enough early human signal to justify its place inside Novo's broader satiety pipeline.
What FormBlends is watching
- Whether Novo gives it any clear strategic identity
- How it sits relative to cagrilintide and amycretin
- Whether the asset keeps moving through the clinic
What could delay the timeline
- Early-stage attrition
- Internal Novo crowding
- A mechanism story that stays too abstract